Progress in bridging therapy of liver transplantation for hepatocellular carcinoma

doi:10.3877/cma.j.issn.1674-3903.2022.01.010

Abstract

Abstract:

Liver transplantation is one of the best treatment options and can bring long-term survival benefits for patients with hepatocellular carcinoma. However, insufficient donor livers have led to some patients being withdrawn from the transplant waiting list. Bridging therapy can control the progression of some hepatocellular carcinoma and reduce the dropout rate of patients waiting for transplantation. Currently, commonly used bridging treatments include interventional therapy, ablation therapy, and radiotherapy. As new systemic and comprehensive strategies have achieved good results in downstaging of advanced hepatocellular carcinoma, whether these methods can be used for bridging therapy also deserves further investigation.

Key words: Hepatocellular carcinoma, Liver transplantation, Bridging therapy

Huinian Zhou, Yumin Li. Progress in bridging therapy of liver transplantation for hepatocellular carcinoma[J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(01): 55-58.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2022.01.010

https://zhyzzz.cma-cmc.com.cn/EN/Y2022/V16/I01/55

References 27

1	Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J]. Gut, 2002, 50(1): 123-128.
2	Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocelhlar carcinoma[J]. Int J Hepatol, 2013：419302.
3	European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485.
4	Thorat A, Lee CF, Wu TH, et al. Safety of transarterial chemoembolization as bridging therapy in HCC patients with hyperbilirubinemia on the waiting list for liver transplantation: a centre experience[J]. Hepatogastroenterology, 2012, 60(128): 2076-2079.
5	Pompili M, Francica G, Ponziani Fit, et al. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation[J]. World J Gastroenterol, 2013, 19(43): 7515-7530.
6	Yu CY, Ou HY, Weng CC, et al. Drug-eluting bead transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before living-donor liver transplantation[J]. Transplant Proc, 2016，48(4)：1045-1048.
7	Lai Q, Vitale A, Iesari S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl, 2019, 25(7)：1023-1033.
8	王浩，高海军，伊正甲，等. 载药微球化疗栓塞治疗在肝癌肝移植术前应用的现状与进展[J]. 国际生物医学工程杂志， 2020, 43(3)：255-259.
9	Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation[J]. Hepatology, 2005, 41(5): 1130-1137.
10	Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study[J]. Ann Surg, 2004, 240(5): 900-909.
11	Cheung TT, Fan ST, Chan SC, et al. High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients[J]. WJG, 2013, 19(20): 3083-3092.
12	Chok KS, Cheung TT, Lo RC，et al. Pilot study of high-intensity focused ultrasound ablation as abridging therapy for hepatocellular carcinoma patients wait-listed for liver trailsplantation[J]. Liver Transpl, 2014, 20(8): 912-921.
13	汪国营. 肝癌肝移植新进展——2019年ILTS年会速递[J]. 器官移植， 2020, 11(1): 47-53.
14	Wong TC, Lee VH, Law AL, et al. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant[J]. Hepatology, 2021, 74(5): 2580-2594.
15	邓斐文，陈焕伟，甄作均. 经颈静脉肝内门体分流术后肝移植单中心经验总结[J/CD]. 实用器官移植电子杂志， 2020, 8(4)：261-266.
16	杨镇，裘法祖. 门脉高压症外科治疗中应重视的几个问题[J]. 肝胆外科杂志， 2000, 8(1)：1-2.
17	冷希圣. 肝移植时代如何看待门静脉高压症的断流手术[J]. 中国现代普通外科进展， 2007, 10(1)：1-4.
18	Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1)：568.
19	Maggiore U, Pascual J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients[J]. Adv Chronic Kidney Dis, 2016, 23(5)：312-316.
20	Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient？[J]. Am J Transplant, 2020, 20(3)：879-883.
21	Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66：101386.
22	崔春晓，杨柳晓，王颖，等．肝癌患者肝移植术前使用PD-1抑制剂对移植后排斥反应的影响[J]. 中国临床医学， 2020, 27(3)：444-447.
23	Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation？[J]. Am J Transplant, 2021, 21(5)：1979-1980.
24	Díaz-Sánchez A, Matilla A, Núñez O, et al. Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival[J]. Gastroenterol Hepatol, 2010，33(3)：155-164.
25	Clavien PA, Lesertel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1)：e11-e22.
26	Cescon M, Cucchetti A, Ravaioli M, et al. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate[J]. J Hepatol, 2013, 58(3)：609-618.
27	Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1)：358-380.

[1]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[2]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[3]	Jie Dong, Song Yang, Hao Yang, Xiang Chen, Wanli Zhang. Relationship between hypermethylation of ACACB gene and clinicopathological factors and survival of hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 433-437.
[4]	Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.
[5]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[6]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[7]	Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[8]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[9]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[10]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[11]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[12]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[13]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[14]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[15]	Fengyun Wu, Xin Teng, Lianjuan Liu. Diagnostic value of high-frequency ultrasonography and enhanced magnetic resonance for primary hyperdifferentiated hepatocellular carcinoma of different diameters [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 404-408.

Please choose a citation manager

Content to export